LandisS.H., MurrayT., BoldenS.Cancer statistics, 1998. CA Cancer J Clin.1998; 48: 6–29.
2.
MillerB.A., RiesL.A.G., HankeyB.F., eds. SEER Cancer Statistics Review: 1973–1990.Bethesda, Md: National Cancer Institute, NIH Pub No 93–2789, 1993.
3.
BalducciL., LymanG.H.Cancer in the elderly. Epidemiologic and clinical implications. Clin Geriatr Med.1997; 13: 1–14.
4.
BrownM.L., FintorL.The economic burden of cancer. Cancer Prevention and Control.New York, NY: Marcel Dekker; 1995.
5.
RileyG.F., PotoskyA.L., LubitzJ.D.Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care.1995; 33: 828–841.
6.
TaplinS.H., BarlowW., UrbanN.Stage, age, comorbidity and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst.1995; 87: 417–426.
7.
BeckJ.R., KassirerJ.P., PaukerS.G.A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med.1982; 73: 883–888.
ReadJ.L., QuinnR.J., BerwickD.M.Preferences for health outcomes. Comparison of assessment methods. Med Decis Making.1984; 4: 315–329.
10.
WeeksJ.Measurement of utilities and quality-adjusted survival. Oncology (Huntingt).1995; 9: 67–70.
11.
GelberR.D., GoldhirschA., CavalliF.Quality of life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study. Ann Intern Med.1991; 114: 621–628.
12.
BrownM.L.The national economic burden of cancer: an update. J Natl Cancer Inst.1990; 82: 1811–1814.
13.
SchuetteH.L., TuckerT.C., BrownM.L.The costs of cancer care in the United States: implications for action. Oncology (Huntingt).1995; 9(suppl 11): 19–22.
14.
VincenzinoJ.V.Health care costs: market forces and reform. Oncology (Huntingt).1995; 9: 367–368.
15.
LymanG.H., KudererN.M., GreeneJ.The economics of febrile neutropenia: implications for the colony-stimulating factors. Eur J Cancer.1998. In press.
16.
SchulmanK.A., YabroffK.R.Measuring the cost-effectiveness of cancer care. Oncology (Huntingt).1995; 9: 523–530.
17.
LymanG.H.Essentials of clinical decision analysis: a new way to think about cancer and age. In: BalducciL., LymanG.H., ErschlerW., eds. Comprehensive Geriatric Oncology.London: Harwood Academic Publishers; 1998: 7–17.
18.
PaukerS.G., KassirerJ.P.Decision analysis. N Engl J Med.1987; 316: 250–258.
19.
DetskyA.S., NaglieI.G.A clinician's guide to cost-effectiveness analysis. Ann Intern Med.1990; 113: 147–154.
20.
UdvarhelyiI.S., ColditzG.A., RaiA.Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?Ann Intern Med.1992; 116: 238–244.
21.
LymanG.H., KudererN.M.The diagnosis and treatment of cancer in the elderly: cost-effectiveness considerations. In: BalducciL., LymanG.H., ErschlerW., eds. Comprehensive Geriatric Oncology.London: Harwood Academic Publishers; 1998: 533–543.
22.
RussellL.B., GoldM.R., SiegelJ.E.Role of cost-effectiveness analysis in health and medicine. Panel on Cost Effectiveness in Health and Medicine. JAMA.1996; 276: 1172–1177.
23.
ExtermannM., OvercashJ., LymanG.H.Comorbidity and functional status are independent in older cancer patients. J Clin Oncol.1998; 16: 1582–1587.
